O Shaughnessy Asset Management LLC Invests $208,000 in Hims & Hers Health, Inc. (NYSE:HIMS)

O Shaughnessy Asset Management LLC purchased a new stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) in the fourth quarter, Holdings Channel reports. The firm purchased 8,601 shares of the company’s stock, valued at approximately $208,000.

Other hedge funds have also bought and sold shares of the company. Vanguard Group Inc. grew its stake in Hims & Hers Health by 11.1% in the 4th quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company’s stock valued at $489,817,000 after purchasing an additional 2,020,722 shares during the period. Arrowstreet Capital Limited Partnership boosted its holdings in shares of Hims & Hers Health by 192.0% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company’s stock worth $152,436,000 after buying an additional 4,145,305 shares during the last quarter. State Street Corp grew its position in Hims & Hers Health by 4.7% during the third quarter. State Street Corp now owns 4,626,543 shares of the company’s stock valued at $85,221,000 after buying an additional 206,078 shares during the period. Geode Capital Management LLC increased its holdings in Hims & Hers Health by 12.7% during the third quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company’s stock worth $79,029,000 after buying an additional 482,177 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in Hims & Hers Health by 7.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,796,838 shares of the company’s stock worth $43,448,000 after acquiring an additional 129,416 shares during the period. 63.52% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on HIMS shares. Citigroup reissued a “sell” rating on shares of Hims & Hers Health in a research report on Wednesday, April 2nd. Canaccord Genuity Group increased their price objective on Hims & Hers Health from $38.00 to $68.00 and gave the company a “buy” rating in a report on Wednesday, February 19th. Morgan Stanley lowered Hims & Hers Health from an “overweight” rating to an “equal weight” rating and boosted their target price for the company from $42.00 to $60.00 in a research note on Tuesday, February 18th. BTIG Research began coverage on Hims & Hers Health in a research note on Tuesday, January 7th. They set a “buy” rating and a $35.00 price target for the company. Finally, Truist Financial lowered their price objective on Hims & Hers Health from $39.00 to $33.00 and set a “hold” rating on the stock in a research note on Thursday. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, Hims & Hers Health presently has a consensus rating of “Hold” and a consensus target price of $38.25.

Hims & Hers Health Trading Up 1.2 %

Shares of Hims & Hers Health stock opened at $27.13 on Monday. The company’s 50-day moving average price is $38.75 and its 200-day moving average price is $30.46. Hims & Hers Health, Inc. has a 12-month low of $11.20 and a 12-month high of $72.98. The company has a market cap of $6.03 billion, a price-to-earnings ratio of 61.66 and a beta of 1.65.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.02. The business had revenue of $481.14 million for the quarter, compared to analysts’ expectations of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. On average, sell-side analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Insider Buying and Selling

In related news, insider Irene Becklund sold 2,203 shares of the company’s stock in a transaction that occurred on Thursday, April 3rd. The shares were sold at an average price of $28.78, for a total value of $63,402.34. Following the transaction, the insider now directly owns 8,007 shares in the company, valued at approximately $230,441.46. This represents a 21.58 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Soleil Boughton sold 54,153 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $29.90, for a total transaction of $1,619,174.70. Following the sale, the insider now owns 165,650 shares of the company’s stock, valued at approximately $4,952,935. The trade was a 24.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 824,303 shares of company stock worth $31,376,661. Corporate insiders own 17.71% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.